NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies develops and commercializes minimally invasive neurosurgical devices for diagnosing and treating brain and pain disorders. Its portfolio centers on FDA-cleared cortical and sEEG electrodes, radiofrequency ablation systems, and related electrode cable assemblies, with commercialization supported in part by a distribution agreement with Zimmer Biomet.

−43,6 %

56,5 %

−39,6 %

+163,5 %

4.44

3.47

— NeuroOne Medical Technologies Corporation
%
Diagnostic electrodes45% Cortical strip/grid and sEEG electrodes used to record and monitor brain activity in epilepsy and related disorders.
Ablation systems35% Radiofrequency ablation products used for functional neurosurgery and pain-related lesioning.
Electrode cable assemblies10% Supporting hardware and cable assemblies sold with the company’s electrode-based systems.
Commercial collaboration revenue10% Milestone and other payments tied to the Zimmer distribution and commercialization arrangement.

The company sells primarily to hospitals, neurosurgeons, and specialty medical centers that diagnose and treat...

  • Neurosurgery hospitals and epilepsy centersprimary

    Buy cortical and sEEG electrodes for diagnosis and monitoring of epilepsy and other brain disorders.

  • Pain management and functional neurosurgery providersprimary

    Buy OneRF ablation systems for lesioning nerve tissue in pain and functional procedures.

  • Distribution partner Zimmer Biometprimary

    Commercializes and distributes selected brain products, helping expand market access.

  • Academic and clinical research institutionssecondary

    Support development, evaluation, and early adoption of new electrode and ablation technologies.

NeuroOne is headquartered and operationally concentrated in the United States, where all employees are located and...

  • •United States is the core operating base and employee location
  • •Commercial activity is centered on U.S. FDA-cleared products
  • •International competition exists, but disclosed operations are U.S.-centric
  • •Physician transparency and compliance rules are a meaningful U.S. exposure
  • •Future foreign expansion would add regulatory and reimbursement complexity

The company’s strategy is to convert FDA clearances into broader commercial adoption across epilepsy, brain ablation,...

01
Broaden commercialization of FDA-cleared productsshort-term

Revenue depends on converting cleared devices into routine clinical use.

02
Advance OneRF TN and other pipeline indicationsmedium-term

New indications can expand the addressable market beyond current products.

03
Leverage Zimmer distributionshort-term

External commercialization support can accelerate market penetration and reduce sales burden.

The business remains highly dependent on regulatory clearance, physician adoption, and successful commercialization of...

high

Failure to commercialize or gain market acceptance

Revenue is concentrated in a small set of neurosurgical products that must win physician adoption.

Scope
Evo Cortical, Evo sEEG, OneRF systems
Materiality
high
high

Dependence on Zimmer for distribution

Zimmer has exclusive global rights for selected brain products, so execution by Zimmer directly affects sales.

Scope
Brain product commercialization
Materiality
high
high

Capital and liquidity risk

The company has recurring losses and needs external funding to support development and commercialization.

Scope
Operating losses, dilution, going-forward funding needs
Materiality
high
medium

Manufacturing and supplier disruption

Products rely on third-party contract manufacturers and outside suppliers, which can constrain output and margins.

Scope
Electrodes, cable assemblies, OneRF products
Materiality
high
medium

Regulatory and compliance burden

Medical devices face FDA, GMP, and Sunshine Act requirements; failures can delay sales or trigger penalties.

Scope
FDA clearance, manufacturing compliance, physician payment reporting
Materiality
high
Revenue recognition for product and collaboration revenue
Can shift quarterly revenue and gross margin
Inventory valuation and excess/obsolete reserves
Affects cost of product revenue and gross profit
Fair value of warrant liability
Can create volatility in net income
Royalty and license obligations
Impacts gross margin and cash outflows

NEUROONE MEDICAL TECHNOLOGIES Corp

NMTC · Surgical & Medical Instruments & Apparatus

Neurogene Inc.

NGNE · Pharmaceutical Preparations

electroCore, Inc.

ECOR · Electromedical & Electrotherapeutic Apparatus

FIREFLY NEUROSCIENCE, INC.

AIFF · Services-Prepackaged Software

BeOne Medicines Ltd.

ONC · Pharmaceutical Preparations

Neuronetics, Inc.

STIM · Surgical & Medical Instruments & Apparatus

: 28.4.2026